Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of everolimus + bevacizumab versus interferon alfa-2a + bevacizumab in first-line metastatic clear cell renal cell carcinoma
2008-000077-38Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) and metastatic renal cell carcinoma (mRCC) comparing Everolimus + bevacizumab with Interferon alfa-2a + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2008; status: completed.
02
Drugs
everolimusbevacizumabinterferon alfa-2a
03
Conditions
clear cell renal cell carcinoma (ccRCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-000077-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000077-38.